Testing OM336 in adults with autoimmune low blood cell counts
Tests OM336 given under the skin in adults with autoimmune blood disorders.
Key facts
- Who runs it
- Lakefront Biotherapeutics West LLC
- Where
- Ann Arbor, Duarte, Seattle, and Washington D.C., United StatesSee the 4 sitesAlso in 1 other country, 3 sites
- Trial code
- Registry title
- OM336 in Autoimmune Cytopenias
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 32 people, planned
- Started
- 1 Aug 2025
- Expected to end
- Sept 2027
- Type of study
- Interventional
- Treatments tested
- OM336
- Record updated
- 3 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with an active autoimmune cytopenia. This is a condition where the immune system lowers blood cell counts, such as warm or cold autoimmune hemolytic anemia or immune thrombocytopenia (ITP).
- Age
- 18 Years to 75 Years
- Sex
- All
- Disease stage
- Active disease that came back or did not respond to treatment (relapsed/refractory).
- Earlier treatment
- At least 1 prior treatment is needed. People who had a BCMA-targeted therapy before cannot join.
Main reasons for not taking part
- Body weight under 55 kg (121 lb)
- Previous treatment with a BCMA-targeted therapy
- Serious infection within 3 months of screening
- Major surgery or spleen removal (splenectomy) within 3 months of screening, or planned during the study
- Pregnant or breastfeeding
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Active autoimmune cytopenia
- Relapsed/refractory after ≥1 prior treatment
- Body weight ≥ 55 kg
- Willing to comply with and study requirements and procedures
Who cannot take part
- Previous treatment with a BCMA-targeted therapy
- Major surgery or splenectomy within 3 months of screening or planned during the study
- Clinically significant infection within 3 months of screening
- Pregnant or breastfeeding
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
Also in 1 other country, 3 sites
- University of MichiganAnn Arbor, United StatesContact: Study SponsorTaking people
- City of HopeDuarte, United StatesContact: Study SponsorTaking people
- Fred Hutchinson Cancer CenterSeattle, United StatesContact: Study SponsorTaking people
- MedstarWashington D.C., United StatesContact: Study SponsorTaking people
About the trial
What the trial wants to find out
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.
The group in the trial
- OM336 Dose EscalationTreatment being tested
Participants will receive OM336 via subcutaneous injection in ascending dose cohorts
Treatment: OM336
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants With Active Autoimmune Cytopenias
- Plain-language title
- Testing OM336 in adults with autoimmune low blood cell countsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT07083960, who can take part
- Record updated
- 3 September 2026